Start Your Search
Jung Kyu Lee
EP1.01 - Advanced NSCLC (ID 150)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 1
- Now Available
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
EP1.01-42 - Is Serum Lymphocyte Count Predictive Biomarker to Identify Lung Cancer Patients Who May Benefit from an Immunotherapy? (Now Available) (ID 2039)
08:00 - 18:00 | Author(s): Jung Kyu Lee
Programmed death ligand 1 (PD-L1) expression is not truly reflected response of immunotherapy. Thus, tumor mutational burden is new biomarker for predict response of immunotherapy. However, sufficient quantity or quality tumor samples must be obtained, so this is limitation. Therefore, we investigated whether high serum lymphocyte is predictive biomarker for immunotherapy response regardless of PD-L1 immunohistochemistry stain among lung cancer patients.Method
We retrospectively analyzed the medical charts of lung cancer patients who treated with immunotherapy (pembrolizumab, nivoluamb, ipilimumab, atezolizumab) at Seoul National University Hospital between April 2016 and March 2019. We evaluated correlation the serum lymphocyte count (SLC) with the progression free survival (PFS) using multivariable linear regression. SLC was evaluated when patientsResult
Total 236 patients treated with immunotherapy for lung cancer. SLC at baseline was not significantly associated with progression free survival (Coeff = -0.00, p = 0.478) after adjustment age, sex, ECOG status, histology and PD L-1 expression status. The 1-year progression free survival rate was 14.8% and patients who survived over 1 year were not revealed difference of SLC compared with those who didn’t survive over 1 year. When we divided two group according lymphocyte count as 5000/uL, among patients who were over 5000/uL of lymphocyte related with increased progression probability (hazard ratio for disease progression, 1.68; 95 % CI, 1.03 to 2.77; P=0.04).
In this study, we revealed that increased serum lymphocyte count over 5000/uL at baseline when immunotherapy start is associated with decreased progression free survival among lung cancer patients who treated with immunotherapy.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.